RxDoctor Payments Data

Jaclyn Sutton

Nurse Practitioner · Boca Raton, FLNPI 1871108738

Payments from drug & device makers

$4,255in general payments, 2019–2025

Across 182 payments — averaging $23.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$634
  • Johnson & Johnson$433
  • Seagen Inc.$317
  • Sanofi$307
  • AstraZeneca$244
  • Merck$241
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$3,94993%
  • Education$3067%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,255 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$5,365
Medicare patients
62
Services billed
104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate28$440,028
LumakrasSotorasib13$275,891
PromactaEltrombopag Olamine17$245,375
EliquisApixaban37$34,444
XareltoRivaroxaban32$24,084
Anagrelide Hcl11$995
Hydroxyurea36$964
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen33$732
Dexamethasone27$290
Anastrozole15$257
Prednisone45$252
Ondansetron OdtOndansetron13$219
Oxycodone Hcl14$161
Methylprednisolone18$158
Gabapentin13$141

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$57$440,02828 claims
AmgenLumakras$20$275,89113 claims
NovartisPromacta$132$245,37517 claims
PfizerEliquis$634$34,44437 claims
Johnson & JohnsonXarelto$433$24,08432 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →